Mycophenolate sodium is an immunosuppressant medicine used to help prevent the body's immune system from rejecting a transplanted organ. It belongs to a class of medicines called antimetabolites, and is an enteric-coated formulation designed to reduce the stomach-related side effects seen with related medicines. It is a prescription-only medicine.

• Therapeutic Class: Immunosuppressant (systemic).

• Pharmacological Class: Inosine monophosphate dehydrogenase (IMPDH) inhibitor.

• Drug Family: Mycophenolic acid derivatives (antimetabolite immunosuppressants).

• ATC Classification: L04AA06 (Mycophenolic acid).

Approved: Prevention of organ rejection in adult and pediatric kidney transplant recipients, used in combination with cyclosporine and corticosteroids.

Commonly used for: Kidney transplant recipients as part of a standard multi-drug immunosuppressive regimen; sometimes used off-label in other transplant types or autoimmune conditions.

Off-label use (only under medical guidance): Used in liver and heart transplant recipients, and in various autoimmune conditions (e.g., lupus nephritis), under specialist guidance, though these are not the core approved indication for this specific formulation.

●       Enteric-coated tablets: 180 mg and 360 mg.

Mycophenolate sodium is converted in the body to its active form, mycophenolic acid, which blocks an enzyme called inosine monophosphate dehydrogenase (IMPDH). This enzyme is needed by lymphocytes (a type of immune cell central to organ rejection) to produce new DNA building blocks for cell division. By blocking this pathway, mycophenolate sodium selectively reduces the proliferation of these immune cells, helping prevent them from attacking the transplanted organ.

• Standard dose (adults): 720 mg taken orally twice daily (a total daily dose of 1,440 mg), used in combination with cyclosporine and corticosteroids.

• Condition-wise dose (children): Dosed based on body surface area, as directed by the pediatric transplant team.

• Route: Oral, on an empty stomach, as tablets that should be swallowed whole and not crushed or chewed (to preserve the enteric coating).

• Missed dose: Take as soon as remembered unless close to the next dose; don't double up.

• Overdose: May increase the risk of infection or low blood counts; requires medical attention.

• Common: Diarrhoea, nausea, vomiting, and low blood counts (particularly white blood cells).

• Serious: Increased risk of infections (including opportunistic infections) and certain cancers (including lymphoma and skin cancers) due to immune suppression, and significant birth defects/pregnancy loss risk if used during pregnancy.

• Emergency symptoms: Signs of serious infection (fever, chills), unusual bruising or bleeding, or severe, persistent diarrhoea.

• Recovery advice: Regular blood count monitoring helps catch low white cell counts early, allowing dose adjustment before infection risk becomes significant; taking the medicine consistently on an empty stomach helps maintain steady drug levels.

• Pregnancy: Contraindicated except in specific, carefully considered circumstances; effective contraception is essential, as detailed in the boxed warning above.

• Breastfeeding: Not recommended during treatment.

• Liver disease: Used with routine monitoring; no formal dose adjustment established for hepatic impairment.

• Kidney disease: Used with caution in patients with severe chronic kidney graft dysfunction; monitored closely.

• Elderly: Used with caution, given a potentially higher risk of certain side effects, including infection, in this age group.

• Children: Approved for pediatric kidney transplant recipients, with body-surface-area-based dosing.

●       Antacids containing magnesium and aluminum: reduce mycophenolate sodium absorption; dosing should be separated.

●       Cholestyramine and other bile acid-binding drugs: can reduce mycophenolic acid absorption, potentially reducing effectiveness.

●       Azathioprine: not typically combined, as both are antimetabolite immunosuppressants with overlapping toxicity (particularly on blood counts).

●       Live vaccines: should generally be avoided during treatment due to the immunosuppressive effect.

●       Complete blood counts regularly, particularly in the first months of treatment.

●       Kidney function and liver function tests periodically.

●       Pregnancy testing before starting in patients who could become pregnant, given the boxed warning.

●       Monitoring for signs of infection throughout treatment.

Mycophenolate mofetil (a related prodrug of the same active molecule, mycophenolic acid, with a different formulation), Azathioprine (an older antimetabolite immunosuppressant).

Used specifically in combination with cyclosporine and corticosteroids as part of the standard triple-immunosuppression regimen for kidney transplant rejection prevention; not typically combined with azathioprine.

●       Organ Transplant / Anti-Rejection Medicines

●       Antimetabolite Immunosuppressants

●       Kidney Transplant Supportive Care

1. Medication Process Of Kidney Transplant Patients

2. Kidney Transplantation Procedure And Cost In India

3. Top Immunosuppressant Medicines After Kidney Transplant -guide

4. Medication Process Of Kidney Transplant Patients

1. https://www.accessdata.fda.gov/drugsatfda_docs/label

2. https://www.drugs.com/dosage/myfortic.html

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.